ATE418562T1 - Ctl epitope des epstein-barr virus - Google Patents
Ctl epitope des epstein-barr virusInfo
- Publication number
- ATE418562T1 ATE418562T1 AT98931834T AT98931834T ATE418562T1 AT E418562 T1 ATE418562 T1 AT E418562T1 AT 98931834 T AT98931834 T AT 98931834T AT 98931834 T AT98931834 T AT 98931834T AT E418562 T1 ATE418562 T1 AT E418562T1
- Authority
- AT
- Austria
- Prior art keywords
- seq
- ebv
- epstein
- barr virus
- ctl epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO7841A AUPO784197A0 (en) | 1997-07-10 | 1997-07-10 | Treatment of nasopharyngeal carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE418562T1 true ATE418562T1 (de) | 2009-01-15 |
Family
ID=3802132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98931834T ATE418562T1 (de) | 1997-07-10 | 1998-07-10 | Ctl epitope des epstein-barr virus |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6723695B1 (de) |
| EP (1) | EP1003773B1 (de) |
| JP (1) | JP2001509514A (de) |
| CN (1) | CN100526331C (de) |
| AT (1) | ATE418562T1 (de) |
| AU (1) | AUPO784197A0 (de) |
| CA (1) | CA2294732A1 (de) |
| DE (1) | DE69840383D1 (de) |
| NZ (1) | NZ501944A (de) |
| WO (1) | WO1999002550A1 (de) |
| ZA (1) | ZA986084B (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2392456A1 (en) * | 1999-11-24 | 2001-05-31 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| WO2004067032A2 (en) | 2003-01-24 | 2004-08-12 | University Of Massachusetts Medical Center | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
| US8067535B2 (en) | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
| FR2850384A1 (fr) * | 2003-01-28 | 2004-07-30 | Centre Nat Rech Scient | Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications |
| US8451808B2 (en) | 2006-02-18 | 2013-05-28 | Intel Corporation | Techniques for 40 megahertz (MHz) channel switching |
| EP1826264A1 (de) * | 2006-02-24 | 2007-08-29 | Deutsches Primatenzentrum GmbH | Primatmodell für Orthopoxvirus-Infektionen |
| GB0706070D0 (en) * | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| CN102812043A (zh) * | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| US20140086888A1 (en) * | 2010-09-01 | 2014-03-27 | Helen E. Heslop | Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc) |
| BR112014014591A8 (pt) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (de) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität |
| US10040827B2 (en) | 2012-03-19 | 2018-08-07 | Deutsches Krebsforschungszentrum | B-cell receptor complex binding proteins containing T-cell epitopes |
| JP2015533366A (ja) | 2012-10-19 | 2015-11-24 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 改良されたヒトヘルペスウイルス免疫療法 |
| CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| US10016494B2 (en) | 2014-02-07 | 2018-07-10 | Valorisation-Hsj, Limited Partnership | Antigenic epitopes from EBV gp350/220 and uses thereof |
| EP3131575B1 (de) | 2014-04-15 | 2024-05-08 | Griffith University | Streptokokken-impfstoffgruppe |
| EP3215165B1 (de) | 2014-11-05 | 2020-12-23 | Memorial Sloan Kettering Cancer Center | Verfahren zur auswahl einer t-zell-linie und spender davon zur adoptiven zelltherapie |
| CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| US10568908B2 (en) | 2015-05-12 | 2020-02-25 | Memorial Sloan Kettering Cancer Center | Methods of treating Epstein-Barr virus-associated lymphoproliferative disorders by T cell therapy |
| KR101794304B1 (ko) * | 2015-09-01 | 2017-11-06 | 가톨릭대학교 산학협력단 | Ebv 항원 특이 t―세포 수용체 및 이의 용도 |
| US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| PT3384052T (pt) * | 2015-12-04 | 2020-06-08 | Singapore Health Serv Pte Ltd | Correlatos clínicos de eficácia de imunoterapia |
| TW201735952A (zh) | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
| CN109475578A (zh) * | 2016-05-25 | 2019-03-15 | 昆士兰医学研究所理事会 | 使用同种异体t细胞治疗自身免疫疾病的方法 |
| DK3507300T3 (da) | 2016-09-02 | 2023-03-27 | Univ James Cook | Sårhelende peptid |
| CA3037002A1 (en) | 2016-09-23 | 2018-03-29 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
| CN106397574A (zh) * | 2016-10-21 | 2017-02-15 | 上海交通大学医学院附属新华医院 | 抗原表位肽及其应用 |
| KR102703633B1 (ko) | 2016-11-09 | 2024-09-05 | 그리피스 유니버시티 | 서브틸라제 세포독소 b 서브유닛 돌연변이체 |
| CN107267481A (zh) * | 2017-05-09 | 2017-10-20 | 上海交通大学医学院附属新华医院 | Cdk5抗原表位肽及其应用 |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| EP3700553A1 (de) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Verfahren für das management von tumorschüben bei der adoptiven immuntherapie |
| NL2023863B1 (en) | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
| MX2022006299A (es) | 2019-11-25 | 2023-01-19 | Univ Griffith | Proteína inmunogénica contra una infección gonocócica. |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰(北京)生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| KR20230107553A (ko) * | 2020-10-07 | 2023-07-17 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 헤르페스바이러스 폴리에피토프 백신 |
| EP4232076A1 (de) | 2020-10-20 | 2023-08-30 | The Chancellor, Masters and Scholars of The University of Oxford | Verfahren und zusammensetzungen zur behandlung von epstein-barr-virus-assoziiertem krebs |
| CN115786509A (zh) * | 2022-10-21 | 2023-03-14 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种鼻咽癌患病风险预测试剂盒 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583564D1 (de) * | 1984-08-23 | 1991-08-29 | Hans Joachim Wolf | Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. |
| US4879213A (en) | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| WO1993019092A1 (fr) | 1992-03-19 | 1993-09-30 | Centre National De La Recherche Scientifique | Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr |
| AU1942595A (en) * | 1994-03-16 | 1995-10-03 | Csl Limited | Cytotoxic t-cell epitopes |
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| MY114769A (en) * | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
| WO1996003144A1 (en) * | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
| AU3072395A (en) * | 1994-07-27 | 1996-02-22 | Csl Limited | Polyepitope vaccines |
| GB9501300D0 (en) * | 1995-01-24 | 1995-03-15 | Boughton Brian J | Peptides which inhibit viruses |
| AUPO007396A0 (en) * | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AU712364B2 (en) * | 1996-05-24 | 1999-11-04 | Council Of The Queensland Institute Of Medical Research, The | EBV CTL epitopes |
-
1997
- 1997-07-10 AU AUPO7841A patent/AUPO784197A0/en not_active Abandoned
-
1998
- 1998-07-09 ZA ZA986084A patent/ZA986084B/xx unknown
- 1998-07-10 EP EP98931834A patent/EP1003773B1/de not_active Expired - Lifetime
- 1998-07-10 NZ NZ501944A patent/NZ501944A/en unknown
- 1998-07-10 JP JP2000502069A patent/JP2001509514A/ja not_active Withdrawn
- 1998-07-10 DE DE69840383T patent/DE69840383D1/de not_active Expired - Fee Related
- 1998-07-10 CN CNB98806992XA patent/CN100526331C/zh not_active Expired - Lifetime
- 1998-07-10 CA CA002294732A patent/CA2294732A1/en not_active Abandoned
- 1998-07-10 AT AT98931834T patent/ATE418562T1/de not_active IP Right Cessation
- 1998-07-10 US US09/462,453 patent/US6723695B1/en not_active Expired - Lifetime
- 1998-07-10 WO PCT/AU1998/000531 patent/WO1999002550A1/en not_active Ceased
-
2003
- 2003-02-03 US US10/356,829 patent/US20030152582A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001509514A (ja) | 2001-07-24 |
| CN1269804A (zh) | 2000-10-11 |
| AUPO784197A0 (en) | 1997-08-07 |
| EP1003773B1 (de) | 2008-12-24 |
| EP1003773A4 (de) | 2002-08-07 |
| CN100526331C (zh) | 2009-08-12 |
| US6723695B1 (en) | 2004-04-20 |
| WO1999002550A8 (en) | 2000-06-15 |
| ZA986084B (en) | 1999-01-26 |
| WO1999002550A1 (en) | 1999-01-21 |
| NZ501944A (en) | 2001-11-30 |
| CA2294732A1 (en) | 1999-01-21 |
| US20030152582A1 (en) | 2003-08-14 |
| DE69840383D1 (de) | 2009-02-05 |
| EP1003773A1 (de) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69840383D1 (de) | Ctl epitope des epstein-barr virus | |
| NZ335612A (en) | A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| BR9814487A (pt) | "vacina" | |
| IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
| CY2570B1 (en) | Compounds for immunotherapy and diagnosis of tuberculosis | |
| EP0726758A4 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus | |
| WO2001058485A3 (en) | Prophylactic and therapeutic antibodies against vaccina virus antigens | |
| GB2301591A (en) | Cytotoxic T-cell epitopes | |
| EP0687182A4 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus | |
| HUP9801266A2 (hu) | Multimer, rekombináns ureázvakcina | |
| CA2192512A1 (en) | Nm03 antibody materials and methods | |
| GB2332907B (en) | EBV CTL Epitopes | |
| EP0770624A3 (de) | Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs | |
| NO920331D0 (no) | Biologisk preparat samt bruk derav | |
| GR3019859T3 (en) | Synthetic vaccine for the specific induction of cytotoxic T-lymphocytes | |
| WO2000055194A3 (en) | Tuberculosis antigens and methods of use therefor | |
| OA09037A (en) | Prevention and treatement of retroviral disease. | |
| WO2002047720A3 (en) | Treatment and prevention of ebv infection and ebv-associated disorders | |
| SE9600436D0 (sv) | Vaccine against hantavirus | |
| AP2001002354A0 (en) | Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses. | |
| NZ316110A (en) | vaccine containing an antigen from H. Influenzae and an antigen from influenza virus | |
| WO2000024876A3 (en) | Spumavirus isolated from humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |